INS and type 1 diabetes mellitus: SAR342434 (SAR-Lis; insulin lispro, Sanofi, Paris, France) has been developed as a biosimilar medicinal product to Humalog in the EU and as a follow-on product in the United States in accordance with the relevant EU and US guidelines.2–6 Similar pharmacokinetic (PK) and pharmacodynamic (PD) profiles were demonstrated for SAR-Lis to both EU-approved and US-approved Ly-Lis and between EU-approved and US-approved Ly-Lis in a PK/PD study in people with T1DM using the euglycemic clamp technique.7